First treatment for common bladder cancer recommended by NICE
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
Read More
Tag: erdafitinib
Janssen reveals data from erdafitinib study
Erdafitinib boosted survival in patients with certain conditions including metastatic urothelial carcinoma
Read More
FDA approves first targeted therapy for metastatic bladder cancer
The decision was based on a clinical trial showing an objective response rate of 32.2%.
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
